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Abstract: Several studies have shown that different control plasmids may cause antitumor action
in different murine tumor models after gene electrotransfer (GET). Due to the differences in
GET protocols, plasmid vectors, and experimental models, the observed antitumor effects were
incomparable. Therefore, the current study was conducted comparing antitumor effectiveness of
three different control plasmids using the same GET parameters. We followed cytotoxicity in vitro
and the antitumor effect in vivo after GET of control plasmids pControl, pENTR/U6 scr and pVAX1
in B16.F10 murine melanoma cells and tumors. Types of cell death and upregulation of selected
cytosolic DNA sensors and cytokines were determined. GET of all three plasmids caused significant
growth delay in melanoma tumors; nevertheless, the effect of pVAX1 was significantly greater than
pControl. While DNA sensors in vivo were not upregulated significantly, cytokines IFN β and
TNF α were upregulated after GET of pVAX1. In vitro, the mRNAs of some cytosolic DNA sensors
were overexpressed after GET; however, with no significant difference among the three plasmids.
In summary, although differences in antitumor effects were observed among control plasmids in vivo,
no differences in cellular responses to plasmid GET were detected in tumor cells in vitro. Thus,
the tumor microenvironment as well as some plasmid properties are most probably responsible for
the antitumor effectiveness.
Keywords: gene electrotransfer; control plasmids; murine melanoma tumor; DNA sensors; cytokines;
antitumor effectiveness
1. Introduction
Gene electrotransfer (GET) is a non-viral delivery method for transfection of cells and tissues [1–3].
The transfer of genetic material across the cell membrane is enabled by a transient increase in the
permeability of cell membrane achieved by exposing the cells to short high voltage electric pulses.
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This process is referred to as electroporation (EP) [4,5]. Most commonly, plasmids; small, circular,
double stranded, extra-chromosomal or episomal DNA molecules, are used for transferring the genes
of interest [6–8]. GET is gaining in importance as delivery system in DNA vaccination and gene
therapy as an alternative approach to viral vectors [9–12].
While GET is an efficient, reliable and safe in vivo transfection method, one of its shortcoming
is the high cell mortality that particular pulse protocols can induce. Cell deaths after GET can
be ascribed to physical damage caused by EP, such as mechanical stress, shear forces, osmotic
stress, heat, and reactive oxygen species. Thus, for different applications of GET, different pulse
protocols should be used and optimized for a particular application. Whereas in intratumoral GET,
when targeting cancer cells, high cell mortality induced by pulse protocol and/or plasmid backbone
could potentially contribute to overall effectiveness, in other GET applications such as vaccination
this phenomenon is undesirable. For the purpose of DNA vaccination, the cells should survive GET
and express the delivered gene of interest in order to get the desired effect [13–15]. Furthermore,
the delivered foreign genetic material can also activate signal transduction cascades that evolved as
warning systems, activated after a eukaryotic cell is exposed to the exogenous danger. For example,
cytosolic DNA sensors can detect foreign DNA as pathogen-associated molecular patterns (PAMPs)
or as damage-associated molecular patterns (DAMPs). Activation of these sensors mediates the
activation of proinflammatory molecules that can trigger an innate and potentiate an adaptive immune
response [16–19].
In several previous studies, we observed that intratumoral GET of different control plasmids
used as controls to therapeutic plasmids produced significant but varying antitumor effectiveness,
suggesting that perhaps the composition of plasmid DNA is an important variable. Increased
expression of several different DNA sensors and cytokines was observed in these studies that could
contribute to antitumor effect [6,17,20–24]. However, due to the differences in GET protocols, control
plasmids and experimental tumors, the observed antitumor effects were incomparable; therefore, the
current study was conducted comparing antitumor effectiveness of three different control plasmids,
using the same GET parameters in B16.F10 murine melanoma tumors. We were especially interested
to discover if the antitumor effectiveness could be correlated to the cytotoxic effect in vitro.
Taken together, our aim in the present study was to follow the cytotoxicity unrelated to a
therapeutic transgene and antitumor effects of intratumoral GET using three different control plasmids
(pControl, pENTR/U6 scr and pVAX1) in B16.F10 murine melanoma cells and tumors. Cytotoxicity and
cell death mechanisms in vitro and tumor growth delay in vivo were determined. Expression of the
mRNAs of selected DNA sensors and cytokines that we previously demonstrated to be overexpressed
in tumor cells were quantified.
2. Results
2.1. In Vivo Gene Electrotransfer of Control Plasmids Resulted in Significant Tumor Growth Delay and
Complete Tumor Regression. These Effects Correlated with an Increased Expression of Cytokine mRNAs
After EP of tumors alone, no significant tumor growth delay was observed (Figure 1, Table 1).
Significant tumor growth delay with respect to control tumors was observed after intratumoral GET
of each control plasmid. Tumor growth delay was more pronounced when pVAX1 (pVAX) was used
than when pControl or pENTR/U6 scr were used in combination with the EP.
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Figure 1. Tumor growth delay after gene electrotransfer (GET) of different control plasmids compared 
to control and electroporation (EP) group. 
Table 1. Calculated tumor growth delay and complete response rate after GET of control plasmids. 
Group N 
Growth Delay (to 40 mm3) (days) 
(AM ± SEM) 
Complete 
Response 
Control 12 0.0 ± 0.4 0 
EP 12 0.7 ± 0.1 0 
pControl + EP 12 4.6 ± 1.5 * 1/12 (8.3%) 
pENTR/U6 scr + EP 12 7.4 ± 0.6 * 3/12 (25%) 
pVAX + EP 6 10.5 ± 2.4 *,** 2/6 (33%) 
AM, arithmetic mean; SEM, standard error of the mean; N = number of parallels in two independent experiments; 
* p < 0.05 statistically significant difference compared to control and EP groups; ** p < 0.05 statistically significant 
difference compared to pControl + EP group. 
Complete tumor regressions after GET of control plasmids were observed in all groups. Paralleling 
the effect on tumor growth, GET of pVAX caused the highest percent (33%) of complete responses. 
For histological analysis of tumors, only the conditions causing a minimal (pControl) and 
maximal (pVAX) antitumor effect were compared to control group and EP group. First, cell death 
mechanisms were observed. Hematoxylin and eosin (HE) staining showed less than 20% of necrosis 
in control, untreated tumors, approximately 40% after GET of pControl, and approximately 60% 
tumor necrosis was observed after GET of pVAX plasmid. Values were normalized to control, 
untreated tumors and shown in Figure 2A. While GET of pVAX caused primarily necrosis, Caspase-
3 staining demonstrated that EP only and GET of pControl caused primarily apoptosis (Figure 2A). 
The proliferation potential of the residual viable part was also assayed by Ki67 staining of tumor 
sections. There was a significant decrease in proliferation after GET of pVAX as well as pControl 
(Figure 2B). Although no statistically significant difference among two plasmids was observed, these 
findings confirmed our previous growth delay observations. 
Figure 1. Tu or gro th delay after gene electrotransfer (GET) of different control plas ids co pared
to control and electroporation (EP) group.
Table 1. Calculated tumor growth delay and complete response rate after GET of control plasmids.
Group N Growth Delay (to 40 mm
3) (days)
(AM ± SEM) Complete Response
Control 12 0.0 ± 0.4 0
EP 12 0.7 ± 0.1 0
pControl + EP 12 4.6 ± 1.5 * 1/12 (8.3%)
pENTR/U6 scr + EP 12 7.4 ± 0.6 * 3/12 (25%)
pVAX + EP 6 10.5 ± 2.4 *,** 2/6 (33%)
AM, arithmetic mean; SEM, standard error of the mean; N = number of parallels in two independent experiments;
* p < 0.05 statistically significant difference compared to control and EP groups; ** p < 0.05 statistically significant
difference compared to pControl + EP group.
Complete tumor regressions after GET of control plasmids were observed in all groups. Paralleling
the effect on tumor growth, GET of pVAX caused the highest percent (33%) of complete responses.
For histological analysis of tumors, only the conditions causing a minimal (pControl) and maximal
(pVAX) antitumor effect were compared to control group and EP group. First, cell death mechanisms
were observed. Hematoxylin and eosin (HE) staining showed less than 20% of necrosis in control,
untreated tumors, approximately 40% after GET of pControl, and approximately 60% tumor necrosis
was observed after GET of pVAX plasmid. Values were normalized to control, untreated tumors and
shown in Figure 2A. While GET of pVAX caused primarily necrosis, Caspase-3 staining demonstrated
that EP only and GET of pControl caused primarily apoptosis (Figure 2A). The proliferation potential
of the residual viable part was also assayed by Ki67 staining of tumor sections. There was a significant
decrease in proliferation after GET of pVAX as well as pControl (Figure 2B). Although no statistically
significant difference among two plasmids was observed, these findings confirmed our previous
growth delay observations.
Cancers 2018, 10, 37 4 of 14
Cancers 2018, 10, x  4 of 14 
 
 
Figure 2. (A) Tumor necrosis (HE) or apoptosis (Caspase-3 positive cells (Casp-3)) after GET of control 
plasmids (B) Proliferation (Ki67 positive cells) of tumor after GET of control plasmids. * p < 0.05 
statistically significant difference compared to control and EP group. ** p < 0.05 statistically significant 
difference compared to control. 
In our previous study, increased expression of IFN β after intratumoral GET of control plasmid 
gWiz Blank was observed in murine melanoma tumor in vivo, therefore we determined the 
expression of IFN β and TNF α after intratumoral GET of the three control plasmids examined in this 
current study [17]. The mRNAs of cytosolic DNA sensors DDX60, p204 and DAI/ZBP1, were also 
examined. Confirming our previous research, all control plasmids examined in this current study 
caused increased expression of IFN β in the tumors. Interestingly, TNF α was significantly increased 
in the tumors only in the pVAX + EP group. DNA sensor mRNAs were not statistically significantly 
upregulated with the exception of p204 after GET of pENTR/U6 scr (Table 2). 
Table 2. Expression of mRNA for DNA sensors (DDX60, DAI/ZBP1, p204) and cytokines (IFN β and 
TNF α) in B16.F10 tumors after GET of control plasmids. 
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DNA Sensors Cytokines 
DDX60  
(AM ± SEM) 
DAI/ZBP1 
(AM ± SEM) 
p204
(AM ± SEM) 
IFN β  
(AM ± SEM) 
TNF α
(AM ± SEM) 
Control 3 1.09 ± 0.31 1.06 ± 0.26 1.22 ± 0.57 1.13 ± 0.42 1.06 ± 0.26 
EP 3 1.05 ± 0.15 0.98 ± 0.18 1.63 ± 0.19 13.27 ± 3.36 0.61 ± 0.12 
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pENTR/U6 scr + EP 6 39.42 ± 20.86 14.16 ± 5.25 15.62 ± 4.49 ** 967.45 ± 184.35 * 5.08 ± 2.47 
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* p < 0.05 statistically significant difference compared to control and EP groups. ** p < 0.05 statistically significant 
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2.2. In Vitro Gene Electrotransfer of Control Plasmids Caused Necrotic Cell Death and Expression of DNA 
Sensor and Signaling Pathway mRNAs  
Delivery of the three plasmids were also tested in vitro to elucidate the mechanisms causing 
tumor growth delay and extensive tumor necrosis. 
After GET of these plasmids, a cytotoxic effect was observed in B16.F10 melanoma cells using a 
metabolic assay. All the plasmids were equally cytotoxic (Figure 3).  
Figure 2. ( ) Tu or necrosis ( E) or apoptosis (Caspase-3 positive cells (Casp-3)) after ET of control
plas ids (B) Proliferation ( i67 positive cells) of tu or after ET of control plas ids. * p < 0.05
statistically significant difference co pared to control and EP group. ** p < 0.05 statistically significant
iffere ce co are to co trol.
In our previous study, increased expression of IFN β after intratumoral GET of control plasmid
gWiz Blank was observed in murine melanoma tumor in vivo, therefore we determined the expression
of IFN β and TNF α after intratumoral GET of the three control plasmids examined in this current
study [17]. The mRNAs of cytosolic DNA sensors DDX60, p204 and DAI/ZBP1, were also examined.
Confirming our previous research, all control plasmids examined in this current study caused increased
expression of IFN β in the tumors. Interestingly, TNF α was significantly increased in the tumors only
in the pVAX + EP group. DNA sensor mRNAs were not statistically significantly upregulated with the
exception of p204 after GET of pENTR/U6 scr (Table 2).
Table 2. Expression of mRNA for DNA sensors (DDX60, DAI/ZBP1, p204) and cytokines (IFN β and













Control 3 1.09 ± 0.31 1.06 ± 0.26 1.22 ± 0.57 1.13 ± 0.42 1.06 ± 0.26
EP 3 1.05 .15 0.98 0.18 1.63 0. 9 13.27 ± 3.36 0.61 0.12
Contol + EP 6 2. 1 0.23 2.43 ± 0.33 3.57 ± 0.61 126.22 ± 20.03 * 9.9 1.63
pENTR/U6 scr + EP 6 39.42 20.86 14.16 5.25 15.62 ± 4.49 ** 967.45 ± 184.35 * 5.08 2.47
pVAX + EP 6 5.21 ± 1.45 5.88 ± 2.55 11.39 ± 2.37 743.48 ± 174.34 * 12.08 ± 2.60 *
AM, arithmetic mean; SEM, stan ard error of the mean; N = number of parallels in two independent experiments;
* p < 0.05 statistically significant difference compared to control and EP groups. ** p < 0.05 statistically significant
difference compared to control, EP and pControl + EP groups, respectively; AM was calculated as the average of
2−∆∆Ct values.
2.2. In Vitro Gene Electrotransfer of Control Plasmids Caused Necrotic Cell Death and Expression of DNA
Sensor and Signaling Pathway mRNAs
Delivery of the three plasmids were also tested in vitro to elucidate the mechanisms causing
tumor growth delay and extensive tumor necrosis.
After GET of these plasmids, a cytotoxic effect was observed in B16.F10 melanoma cells using a
metabolic assay. All the plasmids were equally cytotoxic (Figure 3).
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Figure 3. Cytotoxicity of GET of control plasmids. * p < 0.05 statistically significant difference 
compared to all control groups (no EP) and EP group. 
The cell morphology 20 h after GET of these plasmids was observed after Giemsa staining, in 
which non-damaged tumor cells have clearly visible violet-stained nucleus, while necrotic (damaged) 
cells stain preferably with eosin, resulting in lighter pink staining of the cells. Almost no cell death 
was observed in control samples, whereas a major increase of cell death was observed after EP alone. 
Fragments of dead cells were primarily observed after GET with these plasmids. The findings indicate 
that necrosis is the most likely cell death mechanism after GET of plasmids in vitro (Figure 4).  
 
Figure 4. Giemsa staining showed altered cell morphology after GET of control plasmids. Black 
arrows indicate necrotic cells displaying fragments of cytoplasm and only an outline of the nucleus. 
The mechanism of this cytotoxic effect detected by decreased metabolism and changed 
morphology was determined by flow cytometric analysis of the cells with FITC Annexin V and 7-
AAD. Only cells exposed to EP were measured since we previously observed no cell death in all other 
control groups (data not shown). GET of all three plasmids caused necrotic cell death as indicated by 
high percentages of 7-AAD-positive and Annexin V + 7-AAD-positive cells at 2, 6 and 20 h after GET 
(Figure 5), which confirmed the data obtained by Giemsa staining. The highest percentage of 7-AAD 
positive cells was measured at 2h after GET, indicating on immediate cell death caused by the EP 
alone or by GET, probably due to osmotic unbalance. At later time points, when the cells recovered 
from this immediate stress, a higher percentage of apoptotic and viable cells which started to divide 
were observed, specifically at 20 h (Figure 5).  
Figure 3. Cytotoxicity of GET of control plasmids. * p < 0.05 statistically significant difference compared
to all control groups (no EP) and EP group.
The cell morphology 20 h after GET of these plasmids was observed after Giemsa staining,
in which non-damaged tumor cells have clearly visible violet-stained nucleus, while necrotic (damaged)
cells stain preferably with eosin, resulting in lighter pink staining of the cells. Almost no cell death
was observed in control samples, whereas a major increase of cell death was observed after EP alone.
Fragments of dead cells were primarily observed after GET with these plasmids. The findings indicate
that necrosis is the most likely cell death mechanism after GET of plasmids in vitro (Figure 4).
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Figure 4. Giemsa staining showed altered cell orphology after GET of control plasmids. Black arrows
indicate necrotic cells displaying fragments of cytoplasm and only an outline of the nucleus.
The mech nism of this cytotoxi effect detected by decreased metabolism and ch ged
morphology was determined by flow cytometri analysis of the cells with FITC Annexin V and
7-AAD. Only cells exposed to EP were measured since we previously observe no cell death in all
other control groups (data not shown). GET of all three plasmids caused n crotic cell death as indicated
by high percentages of 7-AAD-positive nd Annexin V + 7-AAD-positive c lls at 2, 6 nd 20 h after
GET (Figure 5), which confirmed the data obtained by Giemsa staining. The highest percentage of
7-AAD positive cells w s measured at 2h after GET, indicating on immediate cell death caus d by the
EP alone or by GET, probably due to osmotic unbalance. At later time points, when the cells recovered
from thi immediate stress, hig er perc ntage of apoptotic and viable cells which started to divide
were observed, specifically at 20 h (Figure 5).
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Figure 5. Percentage of viable cells (negative), apoptotic (Annexin V), late apoptotic/necrotic
(Annexin V + 7 AAD) and necrotic (7 AAD) at 2, 6 and 20 h after GET of control plasmids.
The experiment was repeated twice with three parallels.
Since it was previously observed that GET of gWiz Blank plasmid induced increased expression
of cytosolic DNA sensors and IFN β in B16.F10 melanoma cells, we investigated if the control plasmids
analyzed in the present study had the same effect and if there was any difference among them.
We previously demonstrated that the application of EP alone did not increase the expression of DNA
sensors and IFN β mRNAs [17]. Cytosolic DNA sensors DDX60 and p204 (for all control plasmids) and
DAI/ZBP1 (for pENTR/U6 scr + EP and pVAX + EP) mRNAs were statistically significantly increased
only when compared to control group. No difference in the expression of the cytosolic DNA sensor
mRNAs among the different plasmids was observed. Furthermore, the mRNA level of IFN β as well
as TNF α were not statistically significantly increased comparing different plasmids with each other
(Table 3). IFN β was increased only in pVAX + EP group compared to control untreated cells.
Table 3. Expression of mRNA for cytosolic DNA sensors and pathway activation markers after GET of











Control 8 1.00 ± 0.04 1.01 ± .06 . 0. 1.01 ± 0.05 1.28 ± 0.29
pContol + EP 8 9.30 ± 5.52 * 109.85 ± 24.74 1 . 74.43 ± 27.54 1.69 ± 0.43
pENTR/U6 scr + EP 8 52.74 ± 14.01 * 161.78 ± 54.23 * 68.76 21.38 * 78.90 ± 19.86 2.44 ± 0.98
pVAX + EP 8 62.56 ± 13.29 * 153.85 ± 60.12 * 82.25 ± 28.97 * 102.88 ± 27.46 * 4.35 ± 1.81
AM, arithmetic mean; SEM, standard error of the mean; N = number of parallels in two independent experiments;
* p < 0.05 statistically significant difference compared to control group; AM was calculated as the average of
2−∆∆Ct values.
3. Discussion
Several previous studies have shown that different control plasmids delivered intratumorally by
different GET protocols cause antitumor action in different murine tumor models, including B16.F10
mouse melanomas [17,20–22,25,26]. These actions include tumor growth delay, increased animal
survival, complete tumor regression, and subsequent resistance to tumor cell challenge. The results
of the current study, performed on B16.F10 cells and tumors with a single GET protocol but different
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plasmids, demonstrate that there is no difference in response to the plasmids at the in vitro level;
however, the level of antitumor effect in vivo may be plasmid dependent.
After GET of three different control plasmids to murine B16.F10 melanoma tumors, significant
tumor growth delay was observed. GET of the plasmid pControl had the least potent effect of
the three plasmids, resulting in a low but significant growth delay (4.6 days compared to control
group) and lowest rate of complete responses after treatment (1/12 mice, 8%). Conversely, after GET
of pVAX, growth delay (10 days) and complete response rate (2/6 mice, 33%) were the highest
of the three plasmids and statistically significantly different than after GET of pControl. In other
studies, using different GET protocols pVAX also caused significant tumor growth delay and tumor
regression [20]. Moreover, Marrero et al. also showed that some tumor free mice treated with GET of
pVAX were immune to challenge with B16.F10 tumor cells indicating the involvement of an anti-tumor
adaptive immune response [22]. This corroborated an earlier study in which approximately 70%
of mice with complete tumor regression after GET of control plasmid were resistant to B16.F10 cell
challenge [21]. In studies on larger tumors, the antitumor effect was also present after GET of control
plasmids [17,20,22]. In B16.10 tumors, GET of the plasmid pVAX caused a higher number of complete
response compared to the data obtained in our study on smaller tumors [22]. In our previous study,
another control plasmid, pENTR/U6 scr, also used in this study, produced no growth delay after GET
in a TS/A mammary carcinoma tumor model, which is known as poorly immunogenic or a “cold”
tumor model [8,27–32]. This indicates that the effect of a control plasmid is tumor type specific and that
immunologically “hot” tumors, such as B16.F10 melanomas [17] are more responsive than “cold” ones.
In addition, other tumor related properties, such as metastatic potential, might contributed to different
antitumor effects of control plasmids. Namely, in our previous study, pControl was used as a control
plasmid in two murine melanoma models with high (B16.F10) and low (B16.F1) metastatic potential.
GET of pControl produced a greater growth delay in the low metastatic type of B16 murine melanoma,
B16.F1 melanoma tumors [6]. This further supports the concept that antitumor effectiveness of control
plasmids is also tumor type dependent.
Previous studies indicated on activation of immune response due to the presence of plasmid DNA
in the cells’ cytosol. Thus, we measured the upregulation of cytosolic DNA sensors and cytokines
IFN β and TNF α. With the exception of p204, the expression of DNA sensor mRNAs in vivo was not
significantly increased, which correlated with our previous findings, where only the cytokine IFN β
mRNA was significantly overexpressed, comparable to this study [17]. After GET of pVAX not only IFN
β, but also TNF α mRNA was increased, which is probably associated with an increased proportion
of necrosis and consequently the highest tumor growth delay and complete tumor regression rate.
In contrast to apoptosis, which is a programmed cell death, necrosis is an uncontrolled type of cell
death. During necrosis, the cell membrane is damaged and the cell’s content is released into the
extracellular environment initiating inflammation, thus inducing an intensive immune response.
In vitro, regardless of the plasmid used, the level and type of cell death was the same for the
three control plasmids. Following GET of control plasmids, the upregulation of DNA sensors was
obtained, the mRNA levels of IFN β and TN F α were also increased, but not statistically significant.
Binding and activation of these sensors may lead to the induction of inflammatory responses and cell
necroptosis. The precise factors that influence nucleic acids binding and activation of these sensors are
in general poorly characterized. DAI/ZBP1 [33,34] and DDX60 [35] bind both DNA and RNA. DNA
binding by the human orthologue of p204, IFI16, is be more characterized. This protein cooperatively
assembles on dsDNA greater than 60 bases pairs [36]. Therefore, although these plasmids are very
similar, the structure or sequence of pVAX may better potentiate DNA sensor binding and activation.
Because pENTR/U6 scr produces a small hairpin RNA, and these molecules are known to activate
the RNA sensor RIG-I [37], this additional activation in cell types present in tumors that express
this protein may account for the distinct response to this plasmid. Finally, approximately 15 putative
cytosolic DNA sensors have been described in multiple cell types, and these plasmids could be detected
by a different DNA sensor or activate a different signaling pathway in different cell types, not studied
Cancers 2018, 10, 37 8 of 14
here [18,38,39]. There are several different downstream proteins, such as interleukins (IL-1, IL-12,
IL-18), caspases (Casp-3, Casp-1 and Casp-8), and cyclin-dependent kinase (CDK), that could be also
contribute to the observed effect [18].
The activation of cytosolic DNA sensors in vivo leads to induction of immune response. GET of
control plasmids induces changes in the cytosolic DNA sensor pathway with different downstream
effects, which cannot be directly ascribed to the yet known properties of the construct. The size,
structure, CpG motif content or the difference in antibiotic resistance gene do not appear to play
a role in the level of upregulation of cytosolic DNA sensors, since all three plasmids have similar
characteristics (Table 4 Materials and methods). There are probably some other plasmid characteristics
which are responsible for distinct effects of three control plasmids in the same tumor type B16.F10
as determined in the present study. In addition, the observed antitumor effects in vivo cannot be
ascribed to the direct effects in tumor cells, since the effects in isolated melanoma cells after GET
were the same. Therefore, other factors unrelated to tumor cells must contribute to the observed
antitumor effectiveness.
The tumor microenvironment is composed of many types of cells that can contribute to the
antitumor effectiveness of a particular therapy. In this study GET of pVAX induced a distinct
downstream response from pControl or pENTR/U6 scr in vivo. Non-tumor cells such as tumor
stroma cells, vascular cells, and particularly immune cells are likely to respond differently to GET of
plasmid DNA. These cells may respond by upregulation of different DNA sensors or by no response at
all. This variety of responses may muddle the results of detection assays and account for the lack of
statistical significance in the in vivo studies.
In summary, although differences in antitumor effects were observed among control plasmids
in vivo, no differences in cellular responses to plasmid GET were detected in tumor cells in vitro.
Other cells present in the tumor, including fibroblasts, endothelial cells, and particularly immune cells
may be responsible for the effects. Furthermore, the results of our study demonstrate that not only
the properties of the tumor microenviroment, but also properties related to plasmids contribute to the
observed antitumor effectiveness. These properties are not completely understood, therefore further
studies are needed.
4. Materials and Methods
4.1. Plasmids
Three different control plasmids, two of them pControl [6], pENTR/U6 scr [8] routinely used
in our studies, and the common commercially available plasmid pVAX (pVAX1TM, Thermo Fisher
Scientific, Waltham, MA, USA), which was specifically designed to be used for the development of DNA
vaccines, were used in the experiments. Their characteristics are presented in Table 4. Amplification
of the plasmids was performed in E. coli and plasmids purified using EndoFree Plasmid Mega Kits
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The quality and quantity of
isolated plasmid DNA were determined by spectrophotometric measurements of A260/A280 ratio
(Epoch Microplate Spectrophotometer, Take3™ Micro-Volume Plate, BioTek, Winooski, VT, USA) and
agarose gel electrophoresis (Scie-Plas ltd, Cambridge, UK). The working concentration of 1 mg/mL
(for in vitro experiments) or 4 mg/mL (for in vivo experiments) was prepared in endotoxin-free water.
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Table 4. Comparative analysis of control plasmids’ characteristic, which may potentially contribute to
antitumor effectiveness after in vivo GET.






pVAX1 2999 1.85 × 106 3.25 × 1013 7 2.27 × 1014 CMV kanamycin
pControl 3390 2.09 × 106 2.87 × 1013 10 2.87 × 1014 CMV ampicillin
pENTR/U6 scr 2909 1.79 × 106 3.35 × 1013 13 4.36 × 1014 U6 kanamycin
* with precise sequence, http://scienceprimer.com/nucleotide-molecular-weight-calculator; ** Calculation of
number of mouse specific CpG motifs injected into tumors (100 ug DNA) per Yu et al., 2003; irrespective of relative
immunostimulatory activity [40].
4.2. Cells
The B16.F10 murine melanoma cell line (American Type Culture Collection, Manassas, VA, USA)
was cultured in an advanced minimum essential medium (AMEM; Gibco, Thermo Fisher Scientific),
supplemented with 5% fetal bovine serum (FBS; Gibco), 10 mL/l L-glutamine (GlutaMAX; Gibco), 100 U/mL
penicillin (Grünenthal, Aachen, Germany) and 50 µg/mL gentamicin (Krka, Novo mesto, SIovenia) in
a 5% CO2 humidified incubator at 37 ◦C. The cells were routinely tested and confirmed to be free from
mycoplasma infection, using assay PlasmoTest™—Mycoplasma Detection (Invivogen, Toulouse, France) at
the Institute of Microbiology and Immunology, Medical faculty, University of Ljubljana.
4.3. Animals and Tumors
In the experiments, 6–8 week old female C57Bl/6 mice (Envigo, Udine, Italy) were used. Mice
were housed in specific pathogen-free conditions at a temperature of 20–24 ◦C, relative humidity
55 ± 10% and a 12 h light/dark cycle. Food and water were provided ad libitum. All procedures
were approved by The Administration of the Republic of Slovenia for Food Safety, Veterinary and
Plant Protection (Republic of Slovenia, The Ministry of Agriculture, Forestry and Food, permission
no. 34401-1/2015/7). B16.F10 murine melanoma cells in the exponential growth phase were used for
the induction of subcutaneous tumors with the injection of 1 × 106 cells in 100 µL of saline solution
into the shaved right flank of mice. Tumors were allowed to grow approximately 4 days to reach a
largest diameter of 3 mm before GET was performed (day 0).
4.4. GET in Vitro
B16.F10 cells grown as a monolayer were collected in ice-cold electroporation buffer (125 mM
sucrose, 10 mM K2HPO4, 2.5 mM KH2PO4, 2 mM MgCl2×6H2O). A dense cell suspension was
prepared with a concentration of 25 × 106 cells/mL. Plasmid DNA (11 µL) was added to 44 µL of
prepared cell suspension and 50 µL of the resulting mixture (1 × 106 cells and 10 µg of plasmid) were
electroporated with an electric pulse generator (GT-01, Faculty of Electrical Engineering, University
of Ljubljana, Ljubljana, Slovenia). Eight square-wave electric pulses with a voltage-to-distance ratio
of 600 V/cm, pulse duration of 5 ms and frequency 1 Hz were delivered through two parallel
stainless-steel plate electrodes with a 2 mm gap in between. After the application of electric pulses,
the cells were incubated for 5 min with 100 µL of FBS and then plated in AMEM culture medium
for further assays. Experimental groups were: addition of H2O alone (Control) or combined with
application of electroporation (EP), addition of control plasmids (pControl, pVAX, pENTR/U6 scr)
and GET of control plasmids (pControl + EP, pENTR/U6 scr + EP, pVAX + EP).
4.5. GET in Vivo
In vivo GET of control plasmids was performed on days 0 and 2 after the intratumoral (i.t.)
injection of 100 µg plasmid DNA in 25 µL of endotoxin-free water. To ensure good conductivity in the
contact of the electrodes with the skin, water based gel was applied (Ultragel, Budapest, Hungary).
Ten minutes after plasmid injection, two sets of 4 pulses in perpendicular directions at a frequency of
Cancers 2018, 10, 37 10 of 14
1 Hz, amplitude over distance ratio 600 V/cm and 5 ms duration time were delivered through two
parallel stainless-steel electrodes with a 4 or 6 mm distance between them. The pulses were generated
by an electric pulse generator (ELECTRO cell B10, Betatech, Saint-Orens-de-Gameville, France).
The animals were kept under inhalation anesthesia with 1.5% isoflurane (Izofluran Torrex para 250 mL,
Chiesi Slovenia, Ljubljana, Slovenia) and an oxygen flow of 1 l/min during the entire procedure.
Experimental groups were as follows: Control (i.t. injection of endotoxin-free water), EP
(i.t. injection of endotoxin-free water followed by application of electric pulses), pControl + EP
(i.t. injection of pControl plasmid followed by application of electric pulses), pENTR/U6 scr + EP
(i.t. injection of pENTR/U6 scr plasmid followed by application of electric pulses), pVAX + EP
(i.t. injection of pVAX plasmid followed by application of electric pulses).
4.6. Tumor Growth
Tumor growth was followed after GET to quantify antitumor effects. Tumors were measured
every second day after the first treatment in three orthogonal diameters with a Vernier caliper. Tumor
volumes were calculated using the equation V = a × b × c × π/6. Tumor growth was monitored until
the tumors reached approximately 350 mm3, thereafter the animals were euthanized. The response
of tumors in mice that remained tumor-free for 100 days was termed as complete response. Tumor
growth delay was determined as the difference in time when treated and untreated tumors reach a
tumor volume of 40 mm3. The mice with complete response were excluded from the tumor growth
delay calculation.
4.7. Histology
Three days after the second delivery, three mice from each experimental group were sacrificed and
tumors were excised and fixed in IHC zinc fixative (BD Pharmingen, BD Biosciences, San Jose, CA, USA)
overnight and afterwards embedded in paraffin. Three consecutive 5-µm thick sections were cut from
each paraffin block. The first section of each tumor sample was stained with hematoxylin and eosin (HE)
for the determination of necrosis. The two remaining sections were immunohistochemically stained with
rabbit monoclonal antibodies against Ki-67 (clone SP6, Thermo Fisher Scientific) at dilution 1:1200 for
determination of proliferation of tumor cells or rabbit monoclonal antibodies against Cleaved Caspase-3
(Casp-3, Cell Signalling Technology, Danvers, MA, USA) at dilution 1:1500 for determination of apoptosis.
As the colorogenic reagent a peroxidase-conjugated streptavidin–biotin system (Rabbit specific HRP/DAB
detection IHC kit ab64261, Abcam, Cambridge, UK) was used followed by hematoxylin counterstaining.
Three different fields of immunohistochemically stained sections were captured with a DP72 CCD camera
(Olympus, Hamburg, Germany) connected to a BX-51 microscope (Olympus). Three independent observers
blinded to the treatment groups quantified the percentage of tumor necrosis and the number of Ki-67- or
Casp-3-positive cells on the acquired images.
4.8. Extraction of RNA from Cells or Tumors and Determination of DNA Sensors mRNAs by Quantitative
Real-Time PCR (qPCR)
Four hours after GET in vitro, B16F.10 cells were collected to a cell suspension and centrifuged.
Four hours after GET in vivo, mice were sacrificed and 3–6 tumors per experimental group were
collected, snap frozen in liquid nitrogen, and homogenized in a mortar with a pestle. Total RNA was
extracted from the samples (TRIzol Plus RNA Purification Kit, Thermo Fisher Scientific) according
to the manufacturer’s instructions. The concentration and purity of extracted RNA was determined
spectrophotometrically (Epoch, Winooski, VT, USA) by measurements of absorbance at 260 nm and
of the ratio of absorbance at 260 and 280 nm, respectively. One µg of total RNA of appropriate
purity (260/280 nm ratio = 1.95–2.05) was reverse transcribed into cDNA using SuperScript VILOTM
cDNA Synthesis Kit (Thermo Fisher Scientific), according to the manufacturer’s instructions. Ten-fold
cDNA dilutions were used for qPCR using SYBR Select Master Mix (Thermo Fisher Scientific) and
custom primers for DDX60, DAI/ZBP1, p204, IFN1β and TNFα (Integrated DNA Technologies,
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Coralville, IA, USA) [17]. Quantitative PCR was performed on QuantStudio 3 Real-Time PCR System
(Thermo Fisher Scientific). Relative quantification was performed by comparison to the housekeeping
genes β-actin and glyceraldehyde 3-phosphate dehydrogenase using the ∆∆Ct method [41].
4.9. Cytotoxicity Assay
After GET in vitro, B16.F10 cells from each experimental group were plated in 0.1 mL of cell culture
medium in 96-well plates (Corning Incorporated, Corning, NY, USA). For groups without EP, 1000 cells
were plated in each well and for groups with EP, 2000 cells were plated in each well. Cells were
incubated at 37 ◦C in a 5% CO2 humidified incubator for 3 days. After incubation, Presto Blue® viability
reagent (Thermo Fisher Scientific) in medium was added to the wells and one hour later fluorescence
intensity was measured with a microplate reader (Infinite 200, Tecan, Männedorf, Switzerland).
The survival of cells for groups without EP was normalized to the control group and for groups with
EP to EP group.
4.10. Giemsa Staining
Giemsa staining was performed 20 h after GET of control plasmids in order to observe
morphological changes after GET of control plasmids. For this purpose, cytospins were prepared for
each experimental group as follows: a funnel, labeled microscopy slide, and filter paper were fitted
together and 1 × 103 B16.F10 cells in 80 µL of PBS were added into the funnel. The samples were
centrifuged at 1000 rpm for 4 min in cytocentrifuge (Cytospin 2, Thermo Shandon, Runcorn, UK).
Slides were then air dried, fixed in methanol and stained with Giemsa’s Azure methylene blue solution
(Merck, Darmstadt, Germany) according to the manufacturer’s protocol. Images were captured with a
DP72 CCD camera connected to a BX-51 microscope.
4.11. Determination of Cell Death Mechanism
Cell death mechanisms of B16.F10 cells were determined with a FITC Annexin V Apoptosis
Detection Kit with 7-AAD (BioLegend, San Diego, CA, USA) according to manufacturer’s instructions
2, 6 and 20 hours after GET of control plasmids. The measurements were performed with FACSCanto
II flow cytometer (BD Biosciences, San Jose, CA, USA). 488-nm laser (air-cooled, 20 mW solid state)
was used for the excitation and both 530 and 650-nm band-pass filter were used for detection of green
and red fluorescence. For each cell sample, at least 40000 events were measured. The data were
analyzed by the BD FACSDiva software version 8.0.1 (BD Biosciences, San Jose, CA, USA). All debris
was excluded for further analysis by using FSC/SSC scatter plot. The experiments were performed
twice in 3 parallels.
4.12. Statistical Analysis
Data were first tested for normality of distribution with the Shapiro-Wilk test and were represented
as arithmetic means (AM) with error bars representing standard errors (SEM). The difference among
the groups was evaluated by one-way analysis of variance followed by a Holm-Sidak test for multiple
comparisons to determine the significance among all group or Holm-Sidak test for comparison to
control only (no EP) or EP group. All groups were compared with each other. A p-value of less than
0.05 was considered to be statistically significant. Linear correlation between the results of the two
methods was evaluated by the Pearson’s correlation coefficient. SigmaPlot Software (Systat Software,
Chicago, IL, USA) was used for statistical analysis and graphical representation.
5. Conclusions
In summary, although differences in antitumor effects were observed among control plasmids
in vivo, no differences in cellular responses to plasmid GET were detected in tumor cells in vitro. Other
cells present in the tumor microenvironment, including fibroblasts, endothelial cells, and particularly
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immune cells may be responsible for the effects. Furthermore, also the properties related to plasmids
contribute to the observed antitumor effectiveness.
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